Hypertension and oxidative stress

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 9, 2006, Pages 872-876

  Ward, Natalie C ^a   Croft, Kevin D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antioxidants; Blood pressure; F2 isoprostanes; Hypertension; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; POLYPHENOL DERIVATIVE; TEMPOL; TETRAHYDROBIOPTERIN; TOCOPHEROL DERIVATIVE; ZINC;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; KIDNEY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; DIET; HUMANS; HYPERTENSION; KIDNEY; OXIDATIVE STRESS;

EID: 33747076910     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04457.x     Document Type: Article

References (56)

1. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension 2004; 44: 248-52.
2. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001; 38: 606-11.
3. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: The role of superoxide anion. Hypertension 1999; 34: 539-45.
4. Cracowski J, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002; 23: 360.
5. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 2000; 36: 957-64.
6. Zalba G, San Jose G, Moreno MU et al. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension 2001; 38: 1395-9.
7. Schiffrin EL. Beyond blood pressure: The endothelium and atherosclerosis progression. Am. J. Hypertens. 2002; 15: S115-22.
8. Ortiz MC, Manriquez MC, Romero JC, Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 2001; 38: 655-9.
9. Fleming I, Michaelis UR, Bredenkotter D et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. 2001; 88: 44-51.
10. Sarkis A, Roman RJ. Role of cytochrome p450 metabolites of arachidonic acid in hypertension. Curr. Drug Metab. 2004; 5: 245-56.
11. + channel activity and vascular tone in renal arterioles. Circ. Res. 1998; 83: 1069-79.
12. Ward NC, Rivera J, Hodgson J et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004; 110: 438-43.
13. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic. Biol. Med. 2005; 38: 1032-6.
14. Kase H, Hashikabe Y, Uchida K, Nakanishi N, Hattori Y. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J. Hypertens. 2005; 23: 1375-82.
15. Makino A, Skelton MM, Zou AP, Roman RJ, Cowley Jr AW. Increased renal medullary oxidative stress produces hypertension. Hypertension 2002; 39: 667-72.
16. Zhang Y, Jang R, Mori TA et al. The anti-oxidant Tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat. J. Hypertens. 2003; 21: 1513-18.
17. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic. Res. Commun. 1993; 19: 59-66.
18. Pedro-Botet J, Covas MI, Martin S, Rubies-Prat J. Decreased endogenous antioxidant enzymatic status in essential hypertension. J. Hum. Hypertens. 2000; 14: 343-5.
19. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: Role of heredity, gender, and ethnicity. Hypertension 2000; 36: 878-84.
20. Lip GYH, Edmunds E, Nuttall SL, Landray MJ, Blann AD, Beevers DG. Oxidative stress in malignant and non-malignant phase hypertension. J. Hum. Hypertens. 2002; 16: 333-6.
21. Cracowski JL, Baguet JP, Ormezzano O et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003; 41: 286-8.
22. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: Association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic. Biol. Med. 2004; 36: 226-32.
23. Hamilton CA, Miller WH, Al Benna S et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. 2004; 106: 219-34.
24. Zalba G, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-mediated oxidative stress: Genetic studies of the p22phox gene in hypertension. Antioxid. Redox. Signal. 2005; 7: 1327-36.
25. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: A critical link to hypertension? Am. J. Physiol. Regul. Intergr. Comp. Physiol. 2005; 289: R913-35.
26. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J. Cardiovasc. Pharmacol. 2003; 42: 453-61.
27. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-9.
28. Minuz P, Patrignani P, Gaino S et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106: 2800-5.
29. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol. Renal Physiol. 2000; 279: F544-51.
30. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 1997; 336: 1117-24.
31. Miller III ER, Appel LJ, Risby TH. Effect of dietary patterns on measures of lipid peroxidation: Results from a randomized clinical trial. Circulation 1998; 98: 2390-5.
32. Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 2001; 344: 3-10.
33. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: A randomised controlled trial. Lancet 2002; 359: 1969-74.
34. Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: A randomized controlled trial. J. Hypertens. 2005; 23: 1241-9.
35. Heart Protection Study Collabrative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
36. Blomhoff R. Dietary antioxidants and cardiovascular disease. Curr. Opin. Lipidol. 2005; 16: 47-54.
37. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. Lancet 2003; 361: 2017-23.
38. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004; 110: 637-41.
39. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci. 1997; 92: 361-5.
40. Ward NC, Hodgson JM, Croft KD, Burke V, Beilin LJ, Puddey IB. The combination of vitamin C and grape-seed polyphenols increases blood pressure: A randomized, double-blind, placebo-controlled trial. J. Hypertens. 2005; 23: 427-34.
41. Bates CJ, Walmsley CM, Prentice A, Finch S. Does vitamin C reduce blood pressure? Results of a large study of people aged 65 or older. J. Hypertens. 1998; 16: 925-32.
42. Block G. Ascorbic acid, blood pressure, and the American diet. Ann. N.Y. Acad. Sci. 2002; 959: 180-7.
43. Chen J, He J, Hamm L, Batuman V, Whelton PK. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension 2002; 40: 810-16.
44. Duffy SJ, Gokce N, Holbrook M et al. Treatment of hypertension with ascorbic acid. Lancet 1999; 354: 2048-9.
45. Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. J. Hypertens. 2000; 18: 411-15.
46. Hajjar IM, George V, Sasse EA, Kochar MS. A randomized, doubleblind, controlled trial of vitamin C in the management of hypertension and lipids. Am. J. Ther. 2002; 9: 289-93.
47. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic Acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 2002; 40: 804-9.
48. Kim MK, Sasaki S, Sasazuki S, Okubo S, Hayashi M, Tsugane S. Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension 2002; 40: 797-803.
49. Meydani M. Vitamin E modulation of cardiovascular disease. Ann. N.Y. Acad. Sci. 2004; 1031: 271-9.
50. Miller III ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005; 142: 37-46.
51. Saez GT, Tormos C, Giner V et al. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am. J. Hypertens. 2004; 17: 809-16.
52. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.
53. Taddei S, Virdis A, Ghiadoni L et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens. 2001; 19: 1379-86.
54. On YK, Kim CH, Oh BH, Lee MM, Park YB. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens. Res. 2002; 25: 365-71.
55. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799-805.
56. Taddei S, Virdis A, Ghiadoni L et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943-8.